Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL10584826 | 1.00 | ALDH1A1 (0.31) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL3719747 | 0.94 | ALDH1A1 (0.34) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL5130649 | 0.80 | — | — | |
| SCHEMBL3497998 | 0.78 | — | — | |
| SCHEMBL413416 | 0.78 | — | — | |
| Ethylene Glycol SCHEMBL4563857 | 0.78 | — | — | |
| Ethylene Glycol SCHEMBL243462 | 0.78 | — | — | |
| Ethylene SCHEMBL4367126 | 0.76 | — | — | |
| SCHEMBL1062014 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4942646 | 0.75 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138575-B1 | Conjugates comprising a biodegradable polymer and uses therefor | MERSANA THERAPEUTICS INC (US) | 2013-06-19 | — | — | EP | claimed |
| US-20110044967-A1 | Conjugates Comprising a Biodegradable Polymer and Uses Therefor | THE GENERAL HOSPITAL CORPORATION | 2011-02-24 | — | — | US | claimed |
| EP-2138575-A1 | Conjugates comprising a biodegradable polymer and uses therefor | The General Hospital Corporation (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1585817-B1 | CONJUGATES COMPRISING A BIODEGRADABLE POLYMER AND USES THEREFOR | GEN HOSPITAL CORP (US) | 2009-09-02 | — | — | EP | claimed |
| US-20050169968-A1 | Conjugates comprising a biodegradable polymer and uses therefor | THE GENERAL HOSPITAL CORPORATION | 2005-08-04 | — | — | US | claimed |
| US-20050059068-A1 | Compositions and methods using dendrimer-treated microassays | STRATAGENE CALIFORNIA | 2005-03-17 | — | — | US | claimed |
| WO-1995021380-A1 | ASSAY FOR SCREENING OF RECEPTOR ANTAGONISTS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 1995-08-10 | — | — | WO | claimed |
| US-20160334404-A1 | VALUE-ASSIGNED SOLUTIONS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 HAVING A LONG SHELF-LIFE | DIAZYME LABORATORIES, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-3049813-A2 | LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | Diadexus, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015048177-A2 | LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | DIADEXUS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150086998-A1 | VALUE-ASSIGNED SOLUTIONS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 HAVING A LONG SHELF-LIFE | DIAZYME LABORATORIES, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150086999-A1 | LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | DIAZYME LABORATORIES, INC. | 2015-03-26 | — | — | US | disclosed |
| EP-1920064-B1 | COMPOSITIONS AND METHODS FOR INCREASING AMPLIFICATION EFFICIENCY | QUANTA BIOSCIENCES INC (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2003070823-A9 | CONJUGATES COMPRISING A BIODEGRADABLE POLYMER AND USES THEREFOR | GEN HOSPITAL CORP (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050059068-A1 | Compositions and methods using dendrimer-treated microassays | STRATAGENE CALIFORNIA | 2005-03-17 | — | — | US | disclosed |
| WO-2005002501-A2 | NOVEL DRUGGABLE REGIONS IN THE DENGUE VIRUS ENVELOPE GLYCOPROTEIN AND METHODS OF USING THE SAME | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1447081-A1 | Sugar-modified liposome and products comprising the liposome | National Institue of Advanced Industrial Science and Technology (JP) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003070823-A2 | CONJUGATES COMPRISING A BIODEGRADABLE POLYMER AND USES THEREFOR | THE GENERAL HOSPITAL CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030143267-A1 | Sugar-modified liposome and products comprising the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL | 2003-07-31 | — | — | US | disclosed |
| WO-1995021380-A1 | ASSAY FOR SCREENING OF RECEPTOR ANTAGONISTS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044967-A1 | Conjugates Comprising a Biodegradable Polymer and Uses Therefor | APEH, DNPEP, ENTPD1 | ALDH1A1 1093/4885HMGCR 1531/4885CHRM1 4632/4885 |
| US-20050169968-A1 | Conjugates comprising a biodegradable polymer and uses therefor | APEH, DNPEP, ENTPD1 | ALDH1A1 1093/4885HMGCR 1531/4885CHRM1 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.